The CRC has evolved into a unit with the staff and knowledge base that permits it to organize and conduct Phase I through Phase IV studies. In addition to working with the CONRAD (Contraceptive Research and Development) Program, most major pharma companies and contract research organizations, the CRC has also partnered with WHO, CDC, NIH, NICHD and Family Health International. The CRC's experience has been focused on women's health issues, with expertise gained in pharmacokinetics and must current drug and device delivery systems. The following are areas in which we specialize.

General Gynecology

• Contraception
• Dysmenorrhea
• Endometriosis
• Fibroids
• Menorrhagia
• Atrophic Vaginitis
• Bacterial Vaginosis
• IUD placement
• Follicle monitoring

Endocrine

• Menopausal symptoms/HRT
• Hot flashes
• Osteoporosis
• Sexual Dysfunction
• Low libido
• Dry eyes

Urogynecology

• Stress urinary incontinence
• Overactive bladder
• Mixed urinary incontinence
• Pelvic relaxation/prolapse
• Interstitial cystitis
• Urogenital atrophy

Scientific discovery

• Etiology/mechanisms of uterine bleeding
• Implantation
• Ovarian follicle monitoring
• Male contraception
• Non-hormonal female contraception
• Sperm function
• Cervico-vaginal inflammation
• Microbicides
• Cytokines
• Colposcopy
• Hemizona Assays

IVF

Endometrial Development

Andrology

• Sperm DNA
• Sperm morphology (strict criteria)
• Sperm washing for HIV positive patients
• Sperm egg binding assays
• Spermicidal agents
• Sperm basic analysis
• Sperm motility (CASA)

Obstetrics

• Preterm Labor
• Preeclampsia
• Intrauterine growth restriction
• Patient Safety

Ultra sound

• Fetal Blood Flow
• 3D Sonography
• Fetal cardiovascular physiology
• Doppler in obstetrics
• Ovarian cancer screening
• Uterine malformations

The CRC has worked with a number of pharmaceutical companies and CRO's including:

• Astara Z
• Lipha Pharmaceutical
• Levotech, Inc.
• London International Group
• Barr
• Mead/Johnson
• Berlex
• Merck & Co.
• Abbott Laboratories
• Novartis
• Advanced Care Products
• Novo Nordisk
• Akzo Nobel
• Organon
• Alza Corporation
• Ortho Pharmaceutical Corp.
• American Medical Systems
• Park-Davis
• American Medical Systems
• Park-Davis
• Amylin Pharmaceuticals Inc.
• Path
• Biofilm
• Pfizer, Inc.
• Biosante Pharmaceuticals, Inc.
• Pharmacia & UpJohn
• Biosyn
• Quintiles
• Biotek
• R.W. Johnson Pharmaceutical Research Institute
• Bradstreet
• Reprotect, INC
• Bristol-Myers Squibb
• Rhone-Poulenc Rorer
• Ciba-Geigy Corporation
• Sanofi Research
• Clinical Research International
• Schering-Plough
• CollaGenex Pharmaceuticals, Inc
• Serono Laboratories
• Columbia Research
• SmithKline Beecham
• Corning PACT, Inc.
• Solvay Pharmaceuticals
• Duramed
• Tap Holding, Inc.
• Eli Lilly & Company
• VIVUS, Inc.
• Ethicon
• Wallace Laboratories
• Family Health International
• Warner Chilcott Laboratories
• Fournier Research
• Watson
• Glaxo Smith Kline
• Worldwide Clinical Trials
• Galen
• Wyeth Pharmaceuticals
• Genzyme Corporation
• Xanodyne Pharmaceuticals Inc.
• Gynetics, Inc
• Xenomics
• GynoPharma, Inc.
• Yamanouchi
• Health Decisions
• Zetachron
• Insmed

David F. Archer, MD

Dr. Archer is Professor of Obstetrics and Gynecology at Eastern Virginia Medical School (EVMS) in Norfolk, Virginia. He is board certified in Obstetrics and Gynecology with advanced certification in Reproductive Endocrinology and Infertility. He is the Director of the Contraceptive Research and Development Program (CONRAD) Clinical Research Center, which is housed in the Jones Institute for Reproductive Medicine on the campus of EVMS. He is the Director of the Reproductive Endocrinology and Infertility Fellowship Program in the Division of Reproductive Endocrinology of the Department of Obstetrics and Gynecology.

Dr. Archer has been in the active practice of Reproductive Endocrinology and Infertility since 1970. He has been involved in a variety of clinical research protocols during that time. As Director of the CONRAD Clinical Research Center, he has participated in 200+ clinical protocols related to Women's Health. Fifty-two percent of these protocols have been in contraception, and forth-eight percent in menopause. He has been involved in Phase I through Phase III commercial clinical protocols and contraceptive protocols funded by the CONRAD Program, Family Health International, and the National Institute of Child Health and Human Development (NICHD). He has been the holder of one of the nine Master Agreements of the NICHD Clinical Network for Contraceptive Research (CNCR). As part of the Contraceptive Trial Network, Dr. Archer has participated in trials of a vaginal spermicide, an emergency contraceptive pill, and the efficacy of a vaginal spermicide for contraception. Dr. Archer is a current member of the NICHD Contraceptive Clinical Trial Network (CCTN) inaugurated in 2004. He is one of twelve Principal Investigators for the CCTN, and has two sub-contractors for the current clinical trial of a vaginal contraceptive. He is a NIH grant recipient for the investigation of endometrial bleeding in women using progestin-only contraceptives.

Dr. Archer has published extensively in the area of Reproductive Endocrinology, with a particular interest in the menopause. He is an author or co-author of over 125 peer-reviewed publications. His current research interest is in the mechanisms and control of uterine bleeding, particularly as it relates to progestin-only contraceptives and postmenopausal women using hormone therapy.

Dr. Archer has served on NIH special study sections, and for four years was the chairman of the FDA Maternal and Fertility Drug Advisory Committee. He has also been a member of the World Health Organization Task Force for Long-Acting Hormonal Contraceptives.

Dr. Archer serves as the editor of Menopausal Medicine, a quarterly publication of the American Society of Reproductive Medicine, and is on the editorial board of Contraceptive Technology Update, and Menopause, the journal of the North American Menopause Society. He is an associate editor for Human Reproduction. He is an ad hoc reviewer for Fertility and Sterility, Obstetrics and Gynecology, Steroids, Journal of Clinical Endocrinology and Metabolism, and the American Journal of Obstetrics and Gynecology.

The CRC employs highly qualified employees that are dedicated to research. We operate as a team. Our Principal Investigators are on site.

Clinical Research Coordinators;

• 6 Full time with a total of 50 years research experience
• 4 certified through ACRP
• 4 RNs
• 5 BS/BA, 2 MS

Advertising Recruiting and Marketing- Our in house data base patient hasover 5,000 names of potential volunteers that have contacted us regarding studies. Advertising covers all of the major media including but not limited to TV, Radio, flyers, internet and print.

• 1 Full time manager with more than 15 years of advertising and public relations experience
• 1 Full time recruiter
• 1Part time recruiter/out reach worker

Regulatory Services both local IRB meeting 2 times a month and Central IRB through Chesapeake Research Review Inc.

• 1 Full time regulatory specialist

Laboratory- Phlebotomy, processing and shipping of samples per protocol

• 2 Full time certified medical assistants with IATA certification

Finance and Administrative staff

• 1 Full time financial analyst
• 1 Full time assistant

Obstetrics/Gynecology